시장보고서
상품코드
1151822

세계의 암/종양 프로파일링 시장 예측(-2027년) : 기술별(면역측정, NGS, PCR), 암 종류별(유방암, 폐암, 대장암), 바이오마커 종류별(유전자 바이오마커, 단백질 바이오마커), 용도별(바이오마커 탐색, 진단, 예후)

Cancer/Tumor Profiling Market by Technology (Immunoassay, NGS, PCR), Cancer Type (Breast, Lung, Colorectal), Biomarker Type (Genomic Biomarkers, Protein Biomarkers), Application (Biomarker Discovery, Diagnostics, Prognostics) - Global Forecast to 2027

발행일: | 리서치사: MarketsandMarkets | 페이지 정보: 영문 295 Pages | 배송안내 : 즉시배송

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 암/종양 프로파일링 시장 규모는 2022년 97억 달러에서 2027년에는 160억 달러에 달할 것으로 예측되며, 예측기간 중 CAGR은 10.6%가 됩니다.

시장의 주요 성장 촉진요인으로 암 연구로의 자금 투입 증가와 프로파일링 기술 진화 등을 들 수 있습니다. 또한 맞춤형 의료 인기 확대와 PoC(Point of Care) 진단 수요 증대는 예측기간 중 시장 관계자에게 큰 성장 기회를 제공할 것으로 기대되고 있습니다. 한편 샘플 채취나 보관에 관한 기술적인 과제가 시장 성장을 어느 정도 억제하는 요인이 되고 있습니다.

세계의 암/종양 프로파일링(Cancer/Tumor Profiling) 시장에 대해 분석했으며, 시장의 기본 구조와 최신 상황, 주요 시장 성장 촉진·억제요인, 기술별·암 종류별·바이오마커 종류별·용도별·지역별 시장 동향 전망, 시장 경쟁 상황, 주요 기업 개요 등을 조사했습니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 주요 인사이트

제5장 시장 개요

  • 서론
  • 시장 역학
  • 산업 동향
    • 오믹스 데이터 통합
    • 액체생검 진보
    • 맞춤형 의료를 위한 오가노이드
    • 신규 활성 물질을 개발하기 위한 연구개발(R&D) 투자 증가

제6장 암/종양 프로파일링 시장 : 기술별

  • 서론
  • 면역측정
  • NGS(차세대 시퀀싱)
  • PCR(중합효소 연쇄 반응)
  • In Situ Hybridization
  • 마이크로어레이
  • 질량 분석
  • 기타 기술

제7장 암/종양 프로파일링 시장 : 암 종류별

  • 서론
  • 유방암
  • 폐암
  • 대장암
  • 전립선암
  • 흑색종
  • 기타 암

제8장 암/종양 프로파일링 시장 : 바이오마커 종류별

  • 서론
  • 유전자 바이오마커
  • 단백질 바이오마커
  • 기타 바이오마커

제9장 암/종양 프로파일링 시장 : 용도별

  • 서론
  • 연구 용도
    • 바이오마커 탐색
    • 맞춤형 의료
  • 임상 용도
    • 진단
    • 예후
    • 모니터링·치료
    • 스크리닝

제10장 암/종양 프로파일링 시장 : 지역별

  • 서론
  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 독일
    • 영국
    • 프랑스
    • 이탈리아
    • 스페인
    • 기타 유럽 국가
  • 아시아태평양
    • 일본
    • 중국
    • 인도
    • 기타 아시아태평양 국가
  • 라틴아메리카
  • 중동 및 아프리카

제11장 경쟁 상황

  • 개요
  • 주요 기업이 채용한 전략
  • 주요 기업 매출 점유율 분석
  • 시장 점유율 분석
  • 기업 평가 쿼드런트
  • 경쟁 시나리오
    • 제품 발매·승인
    • 자본 거래
    • 기타

제12장 기업 개요

  • 주요 기업
    • ILLUMINA, INC.
    • QIAGEN N.V.
    • NEOGENOMICS, INC.
    • SYSMEX CORPORATION
    • HTG MOLECULAR DIAGNOSTICS, INC.
    • PREDICTIVE ONCOLOGY, INC.(HELOMICS CORPORATION)
    • CARIS LIFE SCIENCES
    • NANOSTRING TECHNOLOGIES, INC.
    • GUARDANT HEALTH, INC.
    • FOUNDATION MEDICINE, INC.
    • F. HOFFMANN-LA ROCHE LTD
    • THERMO FISHER SCIENTIFIC INC.
    • GENSCRIPT BIOTECH CORPORATION
    • TEMPUS LABS
    • HOLOGIC, INC.
    • EXACT SCIENCES
    • LABORATORY CORPORATION OF AMERICA HOLDINGS
    • PERSONALIS, INC.
  • 기타 기업
    • BOREAL GENOMICS INC.
    • STRAND LIFE SCIENCES
    • LUCENCE HEALTH, INC.
    • ACT GENOMICS CO., LTD.
    • IMB DX, INC.
    • PERTHERA
    • AGENDIA

제13장 부록

KSM 22.11.25

The global cancer/tumor profiling market is projected to reach USD 16.0 Billion by 2027 from USD 9.7 Billion in 2022, at a CAGR of 10.6% during the forecast period. Growth in this market is majorly driven by rising funding investments in cancer research and technological advancements in profiling technologies. In addition, the growing preference for personalized medicine and the growing need for point-of-care diagnostics is expected to offer significant growth opportunities for market players during the forecast period. On the other hand, technical issues with sample collection and storage are factors restraining the market growth to a certain extent.

Based on technology, the immunoassays segment accounted for the largest market share of the cancer/tumor profiling market

Based on technology, the cancer/tumor profiling market has been segmented into immunoassays, in situ hybridization, next-generation sequencing (NGS), polymerase chain reaction (PCR), mass spectrometry, microarrays, and other technologies. The immunoassays segment accounted for the largest market share of in 2021. This large share can be attributed to the its use in the diagnosis and prognosis of cancer, they aid in making appropriate treatment decisions, and adoption of these assays as the gold standard to measure the presence and concentration of analytes in a sample.

Based on cancer type, the lung cancer segment is expected to register the highest CAGR during the forecast period

Based on cancer type, the cancer/tumor profiling market has been segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, and other cancers. During the forecast period, the lung cancer segment is expected to register the highest CAGR. This can be attributed to the increasing need for early diagnosis and the high incidence rate of lung cancer.

Based on biomarker type, the genomic biomarker segment accounted for the largest share during the forecast period

Based on biomarker type, the global cancer/tumor profiling market is segmented into genomic and protein biomarkers. In 2021, the genomic biomarkers segment accounted for the largest share of the cancer/tumor profiling market. The large share of this segment can be attributed to the advancements in high-throughput technologies and high adoption of these biomarkers during cancer diagnosis and prognosis.

Based on applications, the research application segment holds the largest market share during the forecast period

Based on application, the cancer/tumor profiling market has been segmented into research and clinical applications. In 2021, research applications accounted for the largest share of the cancer/tumor profiling market, followed by clinical applications. The large share of the research segment can be attributed to the rapidly growing field of personalized medicine and increasing funding for cancer research.

North America is expected to account for the largest share of the cancer/tumor profiling market in 2021

In 2021, North America accounted for the largest share of the cancer/tumor profiling market, followed by Europe, Asia Pacific, Latin America, and Middle East & Africa. The large share of this market segment can be attributed to the increasing investments for the discovery and development of biomarkers, growing demand for personalized therapeutics and rising adoption of advanced omics technologies for cancer research.

Break of primary participants was as mentioned below:

  • By Company Type - Tier 1-35%, Tier 2-45%, and Tier 3-20%
  • By Designation - C-level-35%, Director-level-25%, Others-40%
  • By Region - North America-45%, Europe-30%, Asia Pacific-20%, Latin America- 5%, Middle East and Africa-5%

Key players in cancer/tumor profiling the market

The key players operating in the cancer/tumor profiling market include Illumina, Inc. (US), QIAGEN N.V. (Germany), NeoGenomics Laboratories, Inc. (US), Sysmex Corporation (Japan), HTG Molecular Diagnostics, Inc. (US), Helomics Corporation (US), Caris Life Sciences (US), NanoString Technologies, Inc. (US), Guardant Health, Inc. (US), and Foundation Medicine (US).

Research Coverage:

The report analyzes the cancer/tumor profiling and aims at estimating the market size and future growth potential of this market based on various segments such as technology, cancer type, biomarker type, application, and region. The report also includes a product portfolio matrix of various cancer/tumor profiling companies available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.

Reasons to Buy the Report

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.

This report provides insights into the following pointers:

  • Market Penetration: Comprehensive information on product portfolios offered by the top players in the global cancer/tumor profiling market. The report analyzes this market by technology, cancer type, biomarker type, application, and region
  • Product Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global cancer/tumor profiling market
  • Market Development: Comprehensive information on the lucrative emerging markets by technology, cancer type, biomarker type, application, and region
  • Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global cancer/tumor profiling market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players in the global cancer/tumor profiling market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
    • 1.2.2 MARKETS COVERED
    • FIGURE 1 CANCER/TUMOR PROFILING MARKET
    • 1.2.3 YEARS CONSIDERED
  • 1.3 CURRENCY CONSIDERED
    • TABLE 1 AVERAGE ANNUAL EXCHANGE RATES USED IN THIS REPORT FOR CURRENCY CONVERSIONS TO USD ARE AS FOLLOWS:
  • 1.4 STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH APPROACH
    • FIGURE 2 RESEARCH DESIGN
    • 2.1.1 SECONDARY RESEARCH
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY RESEARCH
    • FIGURE 3 PRIMARY SOURCES
      • 2.1.2.1 Key data from primary sources
      • 2.1.2.2 Insights from primary experts
      • 2.1.2.3 Breakdown of primaries
    • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.2 MARKET SIZING & VALIDATION APPROACH
    • FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
    • FIGURE 6 CANCER/TUMOR PROFILING MARKET: SEGMENTAL SHARE ANALYSIS
    • FIGURE 7 TOP-DOWN APPROACH
    • FIGURE 8 CAGR PROJECTIONS
    • FIGURE 9 IMPACT ON MARKET GROWTH & CAGR: ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2022-2027)
  • 2.3 DATA TRIANGULATION APPROACH
    • FIGURE 10 DATA TRIANGULATION METHODOLOGY
  • 2.4 MARKET SHARE ESTIMATION
  • 2.5 STUDY ASSUMPTIONS
  • 2.6 LIMITATIONS
    • 2.6.1 METHODOLOGY-RELATED LIMITATIONS
    • 2.6.2 SCOPE-RELATED LIMITATIONS
  • 2.7 RISK ASSESSMENT
    • TABLE 2 RISK ASSESSMENT: CANCER/TUMOR PROFILING MARKET

3 EXECUTIVE SUMMARY

    • FIGURE 11 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
    • FIGURE 12 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022 VS. 2027 (USD MILLION)
    • FIGURE 13 CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022 VS. 2027 (USD MILLION)
    • FIGURE 14 CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
    • FIGURE 15 GEOGRAPHICAL SNAPSHOT OF THE CANCER/TUMOR PROFILING MARKET

4 PREMIUM INSIGHTS

  • 4.1 CANCER/TUMOR PROFILING: MARKET OVERVIEW
    • FIGURE 16 INCREASING INCIDENCE OF CANCER AND RISING PREFERENCE FOR PERSONALIZED MEDICINE TO DRIVE MARKET GROWTH
  • 4.2 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE AND COUNTRY (2021)
    • FIGURE 17 GENETIC BIOMARKERS SEGMENT ACCOUNTED FOR LARGEST SHARE IN 2021
  • 4.3 CANCER/TUMOR PROFILING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 18 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • 4.4 CANCER/TUMOR PROFILING MARKET: REGIONAL MIX (2022-2027)
    • FIGURE 19 APAC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
  • 4.5 CANCER/TUMOR PROFILING MARKET: DEVELOPED VS. EMERGING ECONOMIES (2022 VS. 2027)
    • FIGURE 20 EMERGING ECONOMIES TO REGISTER A HIGHER GROWTH RATE DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 21 CANCER/TUMOR PROFILING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising incidence of cancer
    • FIGURE 22 GLOBAL CANCER INCIDENCE, 2008-2030
      • 5.2.1.2 Increasing use of biomarkers in cancer profiling
      • 5.2.1.3 Growing investments in cancer research
      • 5.2.1.4 Technological advancements in cancer profiling techniques
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High capital investments for biomarker discovery & development
    • TABLE 3 TIMEFRAME FOR BIOMARKER DEVELOPMENT
      • 5.2.2.2 Technical issues related to sample collection & storage
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Growing preference for personalized medicine
    • FIGURE 23 FDA-APPROVED PERSONALIZED MEDICINES, 2015-2021
      • 5.2.3.2 Rising need for point-of-care diagnostics
    • TABLE 4 POC DETECTION TOOLS FOR CANCER (BY CANCER & SAMPLE TYPE)
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Low biomarker discovery-to-approval ratio
    • FIGURE 24 KEY ISSUES AND CHALLENGES IN CLINICAL TRANSLATION OF BIOMARKERS
      • 5.2.4.2 Poor regulatory and reimbursement scenario
    • TABLE 5 CANCER/TUMOR PROFILING MARKET: DRIVES, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • 5.3 INDUSTRY TRENDS
    • 5.3.1 INTEGRATION OF OMICS DATA
    • TABLE 6 CANCER-SPECIFIC MULTI-OMICS DATA RESOURCES
    • 5.3.2 ADVANCES IN LIQUID BIOPSY
    • 5.3.3 ORGANOIDS FOR PERSONALIZED MEDICINE
    • TABLE 7 CLINICAL TRIALS CONDUCTED FOR ASSESSING DRUG SENSITIVITY USING ORGANOID METHODS (2021)
    • 5.3.4 INCREASING R&D INVESTMENTS FOR DEVELOPING NOVEL ACTIVE SUBSTANCES

6 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY

  • 6.1 INTRODUCTION
    • TABLE 8 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018-2021 (USD MILLION)
    • TABLE 9 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2027(USD MILLION)
  • 6.2 IMMUNOASSAYS
    • 6.2.1 PROVISION OF IMPROVED THERAPEUTIC CHOICES FOR DISEASE ASSESSMENT & DIAGNOSIS TO DRIVE MARKET
    • TABLE 10 CANCER/TUMOR PROFILING MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 11 CANCER/TUMOR PROFILING MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022-2027 (USD MILLION)
  • 6.3 NEXT-GENERATION SEQUENCING
    • 6.3.1 RISING ADVANCEMENTS IN NGS TESTS TO DRIVE MARKET
    • TABLE 12 CANCER/TUMOR PROFILING MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 13 CANCER/TUMOR PROFILING MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022-2027 (USD MILLION)
  • 6.4 POLYMERASE CHAIN REACTION
    • 6.4.1 REAL-TIME PCR USED FOR BIOMARKER VALIDATION TO DRIVE MARKET
    • TABLE 14 CANCER/TUMOR PROFILING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 15 CANCER/TUMOR PROFILING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022-2027 (USD MILLION)
  • 6.5 IN SITU HYBRIDIZATION
    • 6.5.1 FISH EVALUATION FOR KEY BIOMARKERS TO DRIVE MARKET
    • TABLE 16 CANCER/TUMOR PROFILING MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 17 CANCER/TUMOR PROFILING MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022-2027 (USD MILLION)
  • 6.6 MICROARRAYS
    • 6.6.1 PREDICTING RECURRENCE OF CANCER POST-TREATMENT TO DRIVE MARKET
    • TABLE 18 CANCER/TUMOR PROFILING MARKET FOR MICROARRAYS, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 19 CANCER/TUMOR PROFILING MARKET FOR MICROARRAYS, BY COUNTRY, 2022-2027 (USD MILLION)
  • 6.7 MASS SPECTROMETRY
    • 6.7.1 RISING TECHNOLOGICAL ADVANCEMENTS FOR RAPID & RELIABLE DIAGNOSTICS TO DRIVE MARKET
    • TABLE 20 CANCER/TUMOR PROFILING MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 21 CANCER/TUMOR PROFILING MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2022-2027 (USD MILLION)
  • 6.8 OTHER TECHNOLOGIES
    • TABLE 22 CANCER/TUMOR PROFILING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 23 CANCER/TUMOR PROFILING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY/REGION, 2022-2027 (USD MILLION)

7 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE

  • 7.1 INTRODUCTION
    • TABLE 24 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018-2021 (USD MILLION)
    • TABLE 25 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022-2027 (USD MILLION)
  • 7.2 BREAST CANCER
    • 7.2.1 RISING RESEARCH COLLABORATIONS ON BREAST CANCER DIAGNOSTICS TO DRIVE MARKET
    • TABLE 26 BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2040
    • TABLE 27 CANCER/TUMOR PROFILING MARKET FOR BREAST CANCER, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 28 CANCER/TUMOR PROFILING MARKET FOR BREAST CANCER, BY COUNTRY, 2022-2027 (USD MILLION)
  • 7.3 LUNG CANCER
    • 7.3.1 MOLECULAR CHARACTERIZATION OF TUMORS USING NGS TO DRIVE MARKET
    • FIGURE 25 GLOBAL LUNG CANCER INCIDENCE, 2012-2030
    • TABLE 29 LUNG CANCER INCIDENCE, BY REGION, 2020 VS. 2040
    • TABLE 30 CANCER/TUMOR PROFILING MARKET FOR LUNG CANCER, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 31 CANCER/TUMOR PROFILING MARKET FOR LUNG CANCER, BY COUNTRY, 2022-2027 (USD MILLION)
  • 7.4 COLORECTAL CANCER
    • 7.4.1 MOLECULAR PROFILING OF PRIMARY CRC TUMORS WITH ADJUVANT THERAPY TO DRIVE MARKET
    • FIGURE 26 COLORECTAL CANCER INCIDENCE RATE FOR KEY COUNTRIES (2018)
    • TABLE 32 COLORECTAL CANCER INCIDENCE, BY REGION, 2020 VS. 2040
    • TABLE 33 CANCER/TUMOR PROFILING MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 34 CANCER/TUMOR PROFILING MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022-2027 (USD MILLION)
  • 7.5 PROSTATE CANCER
    • 7.5.1 DEVELOPMENT OF DIAGNOSTIC & PROGNOSTIC MOLECULAR BIOMARKER TESTS TO DRIVE MARKET
    • FIGURE 27 PROSTATE CANCER INCIDENCE RATE, BY REGION (2020)
    • TABLE 35 CANCER/TUMOR PROFILING MARKET FOR PROSTATE CANCER, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 36 CANCER/TUMOR PROFILING MARKET FOR PROSTATE CANCER, BY COUNTRY, 2022-2027 (USD MILLION)
  • 7.6 MELANOMA
    • 7.6.1 USAGE OF RT-QPCR FOR DETECTION OF MELANOMAS TO DRIVE MARKET
    • TABLE 37 MELANOMA INCIDENCE, BY REGION, 2020 VS. 2040
    • TABLE 38 CANCER/TUMOR PROFILING MARKET FOR MELANOMA, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 39 CANCER/TUMOR PROFILING MARKET FOR MELANOMA, BY COUNTRY, 2022-2027 (USD MILLION)
  • 7.7 OTHER CANCERS
    • FIGURE 28 LEUKEMIA MORTALITY RATE, BY REGION (2020)
    • TABLE 40 CANCER/TUMOR PROFILING MARKET FOR OTHER CANCERS, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 41 CANCER/TUMOR PROFILING MARKET FOR OTHER CANCERS, BY COUNTRY/REGION, 2022-2027 (USD MILLION)

8 CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE

  • 8.1 INTRODUCTION
    • TABLE 42 CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018-2021 (USD MILLION)
    • TABLE 43 CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022-2027 (USD MILLION)
  • 8.2 GENETIC BIOMARKERS
    • 8.2.1 DECISION-MAKING CAPABILITIES FOR TARGETED THERAPIES
    • TABLE 44 CANCER/TUMOR PROFILING MARKET FOR GENETIC BIOMARKERS, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 45 CANCER/TUMOR PROFILING MARKET FOR GENETIC BIOMARKERS, BY COUNTRY, 2022-2027 (USD MILLION)
  • 8.3 PROTEIN BIOMARKERS
    • 8.3.1 HIGH SPECIFICITY FOR CANCER DETECTION & DIAGNOSIS
    • TABLE 46 CANCER/TUMOR PROFILING MARKET FOR PROTEIN BIOMARKERS, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 47 CANCER/TUMOR PROFILING MARKET FOR PROTEIN BIOMARKERS, BY COUNTRY, 2022-2027 (USD MILLION)
  • 8.4 OTHER BIOMARKERS
    • TABLE 48 CANCER/TUMOR PROFILING MARKET FOR OTHER BIOMARKERS, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 49 CANCER/TUMOR PROFILING MARKET FOR OTHER BIOMARKERS, BY COUNTRY, 2022-2027 (USD MILLION)

9 CANCER/TUMOR PROFILING MARKET, BY APPLICATION

  • 9.1 INTRODUCTION
    • TABLE 50 CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2018-2021 (USD MILLION)
    • TABLE 51 CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2027 (USD MILLION)
  • 9.2 RESEARCH APPLICATIONS
    • TABLE 52 CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 53 CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • TABLE 54 CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 55 CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022-2027 (USD MILLION)
    • 9.2.1 BIOMARKER DISCOVERY
      • 9.2.1.1 Development of personalized medicine and drug development to support market
    • TABLE 56 CANCER/TUMOR PROFILING MARKET FOR BIOMARKER DISCOVERY, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 57 CANCER/TUMOR PROFILING MARKET FOR BIOMARKER DISCOVERY, BY COUNTRY, 2022-2027 (USD MILLION)
    • 9.2.2 PERSONALIZED MEDICINE
      • 9.2.2.1 Rising funding activities in precision medicine to support market
    • TABLE 58 CANCER/TUMOR PROFILING MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 59 CANCER/TUMOR PROFILING MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2022-2027 (USD MILLION)
  • 9.3 CLINICAL APPLICATIONS
    • TABLE 60 CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 61 CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • TABLE 62 CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 63 CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY COUNTRY, 2022-2027 (USD MILLION)
    • 9.3.1 DIAGNOSTICS
      • 9.3.1.1 Rising need for early-stage disease diagnosis and innovative product launches to drive market
    • TABLE 64 CANCER/TUMOR PROFILING MARKET FOR DIAGNOSTICS, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 65 CANCER/TUMOR PROFILING MARKET FOR DIAGNOSTICS, BY COUNTRY, 2022-2027 (USD MILLION)
    • 9.3.2 PROGNOSTICS
      • 9.3.2.1 Advancements in molecular biology to drive uptake of tumor profiling
    • TABLE 66 CANCER/TUMOR PROFILING MARKET FOR PROGNOSTICS, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 67 CANCER/TUMOR PROFILING MARKET FOR PROGNOSTICS, BY COUNTRY, 2022-2027 (USD MILLION)
    • 9.3.3 MONITORING & TREATMENT
      • 9.3.3.1 Multiplatform profiling analysis for cancer patients to drive market
    • TABLE 68 CANCER/TUMOR PROFILING MARKET FOR MONITORING & TREATMENT, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 69 CANCER/TUMOR PROFILING MARKET FOR MONITORING & TREATMENT, BY COUNTRY, 2022-2027 (USD MILLION)
    • 9.3.4 SCREENING
      • 9.3.4.1 Screening tests to help high-risk patients ascertain outcomes
    • TABLE 70 CANCER/TUMOR PROFILING MARKET FOR SCREENING, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 71 CANCER/TUMOR PROFILING MARKET FOR SCREENING, BY COUNTRY, 2022-2027 (USD MILLION)

10 CANCER/TUMOR PROFILING MARKET, BY REGION

  • 10.1 INTRODUCTION
    • FIGURE 29 CANCER/TUMOR PROFILING MARKET: GEOGRAPHIC SNAPSHOT (2021)
    • TABLE 72 CANCER/TUMOR PROFILING MARKET, BY REGION, 2018-2021 (USD MILLION)
    • TABLE 73 CANCER/TUMOR PROFILING MARKET, BY REGION, 2022-2027 (USD MILLION)
  • 10.2 NORTH AMERICA
    • TABLE 74 NORTH AMERICA: NEW CANCER CASES, BY CANCER TYPE (2020)
    • FIGURE 30 NORTH AMERICA: CANCER INCIDENCE & MORTALITY, 2012-2035
    • FIGURE 31 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET SNAPSHOT
    • TABLE 75 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 76 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2022-2027 (USD MILLION)
    • TABLE 77 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018-2021 (USD MILLION)
    • TABLE 78 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2027 (USD MILLION)
    • TABLE 79 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018-2021 (USD MILLION)
    • TABLE 80 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022-2027 (USD MILLION)
    • TABLE 81 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018-2021 (USD MILLION)
    • TABLE 82 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022-2027 (USD MILLION)
    • TABLE 83 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 84 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • TABLE 85 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 86 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • 10.2.1 US
      • 10.2.1.1 High R&D investments for cancer biomarker research to drive market
    • TABLE 87 US: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
    • TABLE 88 US: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018-2021 (USD MILLION)
    • TABLE 89 US: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2027 (USD MILLION)
    • TABLE 90 US: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018-2021 (USD MILLION)
    • TABLE 91 US: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022-2027 (USD MILLION)
    • TABLE 92 US: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018-2021 (USD MILLION)
    • TABLE 93 US: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022-2027 (USD MILLION)
    • TABLE 94 US: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 95 US: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • TABLE 96 US: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 97 US: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • 10.2.2 CANADA
      • 10.2.2.1 Rising government initiatives for discovery & development of cancer biomarkers to drive market
    • TABLE 98 CANADA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
    • TABLE 99 CANADA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018-2021 (USD MILLION)
    • TABLE 100 CANADA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2027 (USD MILLION)
    • TABLE 101 CANADA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018-2021 (USD MILLION)
    • TABLE 102 CANADA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022-2027 (USD MILLION)
    • TABLE 103 CANADA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018-2021 (USD MILLION)
    • TABLE 104 CANADA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022-2027 (USD MILLION)
    • TABLE 105 CANADA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 106 CANADA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • TABLE 107 CANADA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 108 CANADA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
  • 10.3 EUROPE
    • FIGURE 32 EUROPE: CANCER INCIDENCE & MORTALITY, 2012-2035
    • TABLE 109 EUROPE: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 110 EUROPE: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2022-2027 (USD MILLION)
    • TABLE 111 EUROPE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018-2021 (USD MILLION)
    • TABLE 112 EUROPE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2027 (USD MILLION)
    • TABLE 113 EUROPE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018-2021 (USD MILLION)
    • TABLE 114 EUROPE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022-2027 (USD MILLION)
    • TABLE 115 EUROPE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018-2021 (USD MILLION)
    • TABLE 116 EUROPE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022-2027 (USD MILLION)
    • TABLE 117 EUROPE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 118 EUROPE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • TABLE 119 EUROPE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 120 EUROPE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • 10.3.1 GERMANY
      • 10.3.1.1 Favorable government health policies to drive market
    • TABLE 121 GERMANY: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
    • TABLE 122 GERMANY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018-2021 (USD MILLION)
    • TABLE 123 GERMANY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2027 (USD MILLION)
    • TABLE 124 GERMANY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018-2021 (USD MILLION)
    • TABLE 125 GERMANY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022-2027 (USD MILLION)
    • TABLE 126 GERMANY: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018-2021 (USD MILLION)
    • TABLE 127 GERMANY: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022-2027 (USD MILLION)
    • TABLE 128 GERMANY: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 129 GERMANY: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • TABLE 130 GERMANY: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 131 GERMANY: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • 10.3.2 UK
      • 10.3.2.1 Availability of government funding and strategic collaborations with biotech firms to drive market
    • TABLE 132 UK: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
    • TABLE 133 UK: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018-2021 (USD MILLION)
    • TABLE 134 UK: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2027 (USD MILLION)
    • TABLE 135 UK: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018-2021 (USD MILLION)
    • TABLE 136 UK: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022-2027 (USD MILLION)
    • TABLE 137 UK: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018-2021 (USD MILLION)
    • TABLE 138 UK: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022-2027 (USD MILLION)
    • TABLE 139 UK: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 140 UK: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • TABLE 141 UK: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 142 UK: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • 10.3.3 FRANCE
      • 10.3.3.1 Growing government investments in genomics & proteomics research to drive market
    • TABLE 143 FRANCE: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
    • TABLE 144 FRANCE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018-2021 (USD MILLION)
    • TABLE 145 FRANCE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2027 (USD MILLION)
    • TABLE 146 FRANCE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018-2021 (USD MILLION)
    • TABLE 147 FRANCE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022-2027 (USD MILLION)
    • TABLE 148 FRANCE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018-2021 (USD MILLION)
    • TABLE 149 FRANCE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022-2027 (USD MILLION)
    • TABLE 150 FRANCE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 151 FRANCE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • TABLE 152 FRANCE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 153 FRANCE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • 10.3.4 ITALY
      • 10.3.4.1 Rising research activities for discovery of novel cancer biomarkers using tissue diagnostics to drive market
    • TABLE 154 ITALY: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
    • TABLE 155 ITALY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018-2021 (USD MILLION)
    • TABLE 156 ITALY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2027 (USD MILLION)
    • TABLE 157 ITALY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018-2021 (USD MILLION)
    • TABLE 158 ITALY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022-2027 (USD MILLION)
    • TABLE 159 ITALY: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018-2021 (USD MILLION)
    • TABLE 160 ITALY: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022-2027 (USD MILLION)
    • TABLE 161 ITALY: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 162 ITALY: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • TABLE 163 ITALY: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 164 ITALY: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • 10.3.5 SPAIN
      • 10.3.5.1 Rising incidence of cancer to drive demand for biomarkers
    • TABLE 165 SPAIN: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
    • TABLE 166 SPAIN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018-2021 (USD MILLION)
    • TABLE 167 SPAIN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2027 (USD MILLION)
    • TABLE 168 SPAIN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018-2021 (USD MILLION)
    • TABLE 169 SPAIN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022-2027 (USD MILLION)
    • TABLE 170 SPAIN: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018-2021 (USD MILLION)
    • TABLE 171 SPAIN: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022-2027 (USD MILLION)
    • TABLE 172 SPAIN: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 173 SPAIN: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • TABLE 174 SPAIN: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 175 SPAIN: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • 10.3.6 REST OF EUROPE (ROE)
    • TABLE 176 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018-2021 (USD MILLION)
    • TABLE 177 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2027 (USD MILLION)
    • TABLE 178 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018-2021 (USD MILLION)
    • TABLE 179 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022-2027 (USD MILLION)
    • TABLE 180 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018-2021 (USD MILLION)
    • TABLE 181 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022-2027 (USD MILLION)
    • TABLE 182 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 183 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • TABLE 184 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 185 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
  • 10.4 ASIA PACIFIC
    • FIGURE 33 ASIA PACIFIC: CANCER INCIDENCE & MORTALITY, 2012-2035
    • FIGURE 34 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET SNAPSHOT
    • TABLE 186 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 187 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2022-2027 (USD MILLION)
    • TABLE 188 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018-2021 (USD MILLION)
    • TABLE 189 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2027 (USD MILLION)
    • TABLE 190 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018-2021 (USD MILLION)
    • TABLE 191 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022-2027 (USD MILLION)
    • TABLE 192 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018-2021 (USD MILLION)
    • TABLE 193 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022-2027 (USD MILLION)
    • TABLE 194 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 195 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, Y TYPE, 2022-2027 (USD MILLION)
    • TABLE 196 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 197 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • 10.4.1 JAPAN
      • 10.4.1.1 Increasing initiatives to boost genomic research to support market
    • TABLE 198 JAPAN: CANCER INCIDENCE BY CANCER TYPE, 2020 VS. 2040
    • TABLE 199 JAPAN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018-2021 (USD MILLION)
    • TABLE 200 JAPAN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2027 (USD MILLION)
    • TABLE 201 JAPAN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018-2021 (USD MILLION)
    • TABLE 202 JAPAN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022-2027 (USD MILLION)
    • TABLE 203 JAPAN: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018-2021 (USD MILLION)
    • TABLE 204 JAPAN: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022-2027 (USD MILLION)
    • TABLE 205 JAPAN: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 206 JAPAN: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • TABLE 207 JAPAN: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 208 JAPAN: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • 10.4.2 CHINA
      • 10.4.2.1 Rising government investments in genomics technologies to drive demand for tumor profiling products
    • TABLE 209 CHINA: CANCER INCIDENCE BY CANCER TYPE, 2020 VS. 2040
    • TABLE 210 CHINA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018-2021 (USD MILLION)
    • TABLE 211 CHINA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2027 (USD MILLION)
    • TABLE 212 CHINA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018-2021 (USD MILLION)
    • TABLE 213 CHINA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022-2027 (USD MILLION)
    • TABLE 214 CHINA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018-2021 (USD MILLION)
    • TABLE 215 CHINA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022-2027 (USD MILLION)
    • TABLE 216 CHINA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 217 CHINA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • TABLE 218 CHINA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 219 CHINA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • 10.4.3 INDIA
      • 10.4.3.1 Rising demand for early cancer diagnosis due to increasing cancer burden to support market
    • TABLE 220 INDIA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
    • TABLE 221 INDIA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018-2021 (USD MILLION)
    • TABLE 222 INDIA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2027 (USD MILLION)
    • TABLE 223 INDIA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018-2021 (USD MILLION)
    • TABLE 224 INDIA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022-2027 (USD MILLION)
    • TABLE 225 INDIA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018-2021 (USD MILLION)
    • TABLE 226 INDIA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022-2027 (USD MILLION)
    • TABLE 227 INDIA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 228 INDIA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • TABLE 229 INDIA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 230 INDIA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • 10.4.4 REST OF ASIA PACIFIC (ROAPAC)
    • TABLE 231 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018-2021 (USD MILLION)
    • TABLE 232 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2027 (USD MILLION)
    • TABLE 233 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018-2021 (USD MILLION)
    • TABLE 234 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022-2027 (USD MILLION)
    • TABLE 235 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018-2021 (USD MILLION)
    • TABLE 236 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022-2027 (USD MILLION)
    • TABLE 237 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 238 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • TABLE 239 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 240 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
  • 10.5 LATIN AMERICA
    • 10.5.1 GROWING RESEARCH ACTIVITIES IN PRECISION ONCOLOGY TO SUPPORT MARKET
    • TABLE 241 LATIN AMERICA: CANCER INCIDENCE BY CANCER TYPE, 2020 VS. 2040
    • TABLE 242 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018-2021 (USD MILLION)
    • TABLE 243 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2027 (USD MILLION)
    • TABLE 244 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018-2021 (USD MILLION)
    • TABLE 245 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022-2027 (USD MILLION)
    • TABLE 246 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018-2021 (USD MILLION)
    • TABLE 247 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022-2027 (USD MILLION)
    • TABLE 248 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 249 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • TABLE 250 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 251 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
  • 10.6 MIDDLE EAST & AFRICA
    • 10.6.1 GROWING ESTABLISHMENT OF PHARMA RESEARCH COMPANIES TO DRIVE DEMAND FOR CANCER DIAGNOSTICS
    • TABLE 252 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018-2021 (USD MILLION)
    • TABLE 253 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2027 (USD MILLION)
    • TABLE 254 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018-2021 (USD MILLION)
    • TABLE 255 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022-2027 (USD MILLION)
    • TABLE 256 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018-2021 (USD MILLION)
    • TABLE 257 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022-2027 (USD MILLION)
    • TABLE 258 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 259 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • TABLE 260 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 261 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 STRATEGIES ADOPTED BY KEY PLAYERS
  • 11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
  • 11.4 MARKET SHARE ANALYSIS
    • FIGURE 36 NEXT-GENERATION SEQUENCING MARKET SHARE, BY KEY PLAYER (2021)
    • FIGURE 37 PCR TECHNOLOGIES MARKET SHARE, BY KEY PLAYER (2021)
    • FIGURE 38 IMMUNOASSAYS MARKET SHARE, BY KEY PLAYER (2021)
  • 11.5 COMPANY EVALUATION QUADRANT
    • 11.5.1 STARS
    • 11.5.2 EMERGING LEADERS
    • 11.5.3 PERVASIVE PLAYERS
    • 11.5.4 PARTICIPANTS
    • FIGURE 39 CANCER/TUMOR PROFILING MARKET: COMPANY EVALUATION QUADRANT (2021)
  • 11.6 COMPETITIVE SCENARIO
    • 11.6.1 PRODUCT LAUNCHES & APPROVALS
    • TABLE 262 PRODUCT LAUNCHES & APPROVALS (JANUARY 2019-OCTOBER 2022)
    • 11.6.2 DEALS
    • TABLE 263 DEALS (JANUARY 2019-OCTOBER 2022)
    • 11.6.3 OTHERS
    • TABLE 264 OTHERS (JANUARY 2019-OCTOBER 2022)

12 COMPANY PROFILES

  • 12.1 KEY PLAYERS
  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
    • 12.1.1 ILLUMINA, INC.
    • TABLE 265 ILLUMINA, INC: BUSINESS OVERVIEW
    • FIGURE 40 ILLUMINA, INC: COMPANY SNAPSHOT (2021)
    • 12.1.2 QIAGEN N.V.
    • TABLE 266 QIAGEN N.V.: BUSINESS OVERVIEW
    • FIGURE 41 QIAGEN N.V.: COMPANY SNAPSHOT (2021)
    • 12.1.3 NEOGENOMICS, INC.
    • TABLE 267 NEOGENOMICS, INC: BUSINESS OVERVIEW
    • FIGURE 42 NEOGENOMICS, INC: COMPANY SNAPSHOT (2021)
    • 12.1.4 SYSMEX CORPORATION
    • TABLE 268 SYSMEX CORPORATION: BUSINESS OVERVIEW
    • FIGURE 43 SYSMEX CORPORATION: COMPANY SNAPSHOT (2021)
    • 12.1.5 HTG MOLECULAR DIAGNOSTICS, INC.
    • TABLE 269 HTG MOLECULAR DIAGNOSTICS, INC.: BUSINESS OVERVIEW
    • FIGURE 44 HTG MOLECULAR DIAGNOSTICS, INC: COMPANY SNAPSHOT (2021)
    • 12.1.6 PREDICTIVE ONCOLOGY, INC. (HELOMICS CORPORATION)
    • TABLE 270 PREDICTIVE ONCOLOGY, INC.: BUSINESS OVERVIEW
    • FIGURE 45 PREDICTIVE ONCOLOGY, INC: COMPANY SNAPSHOT (2021)
    • 12.1.7 CARIS LIFE SCIENCES
    • TABLE 271 CLARIS LIFE SCIENCES: BUSINESS OVERVIEW
    • 12.1.8 NANOSTRING TECHNOLOGIES, INC.
    • TABLE 272 NANOSTRING TECHNOLOGIES, INC.: BUSINESS OVERVIEW
    • FIGURE 46 NANOSTRING TECHNOLOGIES, INC: COMPANY SNAPSHOT (2021)
    • 12.1.9 GUARDANT HEALTH, INC.
    • TABLE 273 GUARDANT HEALTH, INC: BUSINESS OVERVIEW
    • FIGURE 47 GUARDANT HEALTH, INC: COMPANY SNAPSHOT (2021)
    • 12.1.10 FOUNDATION MEDICINE, INC.
    • TABLE 274 FOUNDATION MEDICINE, INC.: BUSINESS OVERVIEW
    • 12.1.11 F. HOFFMANN-LA ROCHE LTD
    • TABLE 275 F. HOFFMANN-LA ROCHE LTD: BUSINESS OVERVIEW
    • FIGURE 48 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2021)
    • 12.1.12 THERMO FISHER SCIENTIFIC INC.
    • TABLE 276 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
    • FIGURE 49 THERMO FISHER SCIENTIFIC INC: COMPANY SNAPSHOT (2021)
    • 12.1.13 GENSCRIPT BIOTECH CORPORATION
    • TABLE 277 GENSCRIPT BIOTECH CORPORATION: BUSINESS OVERVIEW
    • FIGURE 50 GENSCRIPT BIOTECH CORPORATION: COMPANY SNAPSHOT (2021)
    • 12.1.14 TEMPUS LABS
    • TABLE 278 TEMPUS LABS: BUSINESS OVERVIEW
    • 12.1.15 HOLOGIC, INC.
    • TABLE 279 HOLOGIC, INC: BUSINESS OVERVIEW
    • FIGURE 51 HOLOGIC, INC: COMPANY SNAPSHOT (2021)
    • 12.1.16 EXACT SCIENCES
    • TABLE 280 EXACT SCIENCES: BUSINESS OVERVIEW
    • FIGURE 52 EXACT SCIENCES: COMPANY SNAPSHOT (2021)
    • 12.1.17 LABORATORY CORPORATION OF AMERICA HOLDINGS
    • TABLE 281 LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS OVERVIEW
    • FIGURE 53 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2021)
    • 12.1.18 PERSONALIS, INC.
    • TABLE 282 PERSONALIS, INC: BUSINESS OVERVIEW
    • FIGURE 54 PERSONALIS, INC.: COMPANY SNAPSHOT (2021)
  • 12.2 OTHER PLAYERS
    • 12.2.1 BOREAL GENOMICS INC.
    • TABLE 283 BOREAL GENOMICS, INC: BUSINESS OVERVIEW
    • 12.2.2 STRAND LIFE SCIENCES
    • TABLE 284 STRAND LIFE SCIENCES: BUSINESS OVERVIEW
    • 12.2.3 LUCENCE HEALTH, INC.
    • TABLE 285 LUCENCE HEALTH, INC.: BUSINESS OVERVIEW
    • 12.2.4 ACT GENOMICS CO., LTD.
    • TABLE 286 ACT GENOMICS CO., LTD.: BUSINESS OVERVIEW
    • 12.2.5 IMB DX, INC.
    • TABLE 287 IMB DX, INC.: BUSINESS OVERVIEW
    • 12.2.6 PERTHERA
    • TABLE 288 PERTHERA: BUSINESS OVERVIEW
    • 12.2.7 AGENDIA
    • TABLE 289 AGENDIA: BUSINESS OVERVIEW
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 INSIGHTS FROM INDUSTRY EXPERTS
  • 13.2 DISCUSSION GUIDE
  • 13.3 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.4 CUSTOMIZATION OPTIONS
  • 13.5 RELATED REPORTS
  • 13.6 AUTHOR DETAILS
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제